Novel high molecular weight albumin-conjugated angiotensin II activates β-arrestin and G-protein pathways

Hong Weng Pang, Andrea Linares, Leena Couling, Jessica Santollo, Leonardo Ancheta, Derek Daniels, Robert C. Speth

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Purpose: To study the ability of a novel bovine serum albumin-angiotensin II (BSA-Ang II) conjugate to effect responses of the AT1 angiotensin II receptor subtype mediated by the G-protein-coupled and the beta-arrestin pathways. Methods: Angiotensin II (Ang II) was conjugated with bovine serum albumin and compared with Ang II for competition binding to AT1 receptors, to stimulate aldosterone release from adrenocortical cells, to promote beta-arrestin binding to AT1 receptors, to promote calcium mobilization, and stimulate drinking of water and saline by rats. Results: The BSA-Ang II conjugate was less potent competing for AT1R binding, but was equally efficacious at stimulating aldosterone release from H295R adrenocortical cells. Both BSA-Ang II and Ang II stimulated calcium mobilization and beta-arrestin binding to AT1 receptors. BSA-Ang II and Ang II stimulated water appetite equivalently but BSA-Ang II stimulated saline appetite more than Ang II. Both BSA-Ang II and Ang II were considerably more potent at causing calcium mobilization than β-arrestin binding. Conclusions: Addition of a high molecular weight molecule to Ang II reduced its AT1 receptor binding affinity, but did not significantly alter stimulation of aldosterone release or water consumption. The BSA-Ang II conjugate caused a greater saline appetite than Ang II suggesting that it may be a more efficacious agonist of this beta-arrestin-mediated response than Ang II. The higher potency calcium signaling response suggests that the G-protein-coupled responses predominate at physiological concentrations of Ang II, while the beta-arrestin response requires pathophysiological or pharmacological concentrations of Ang II to occur.

Original languageEnglish
Pages (from-to)349-359
Number of pages11
JournalEndocrine
Volume66
Issue number2
DOIs
StatePublished - Nov 1 2019

Bibliographical note

Publisher Copyright:
© 2019, Springer Science+Business Media, LLC, part of Springer Nature.

Funding

Acknowledgements The authors thank Dr. Anastasios Lymperopoulos for assistance in experimental design and Dr. Douglas Lappi and Denise Higgins for editorial suggestions. This study was funded by a President’s Faculty Research Development Grant from Nova South-eastern University and the Cardiovascular Neuroscience Fund, Nova Southeastern University and NIH, HL-113905.

FundersFunder number
Nova South-eastern University
National Institutes of Health (NIH)HL-113905
Author National Institute on Drug Abuse DA031791 Mark J Ferris National Institute on Drug Abuse DA006634 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA026117 Mark J Ferris National Institute on Alcohol Abuse and Alcoholism AA028162 Elizabeth G Pitts National Institute of General Medical Sciences GM102773 Elizabeth G Pitts Peter McManus Charitable Trust Mark J Ferris National Institute on Drug AbuseK12DA035150
Nova Southeastern University

    Keywords

    • AT1 receptor
    • Aldosterone release
    • Biased agonism
    • Bovine serum albumin-conjugated angiotensin II
    • Calcium mobilization
    • Salt appetite

    ASJC Scopus subject areas

    • Endocrinology, Diabetes and Metabolism
    • Endocrinology

    Fingerprint

    Dive into the research topics of 'Novel high molecular weight albumin-conjugated angiotensin II activates β-arrestin and G-protein pathways'. Together they form a unique fingerprint.

    Cite this